Thanks for posting this here! And surprising its attracting attention, I have to imagine that the TAM for 2-hour-long biologics-manufacturing podcasts is small :)

If you're more interested in this person's work, his website is here: https://www.iku.bio/

I'm going to be honest: I have absolutely no idea what this comment means

I’m sure it was positive, whatever it said.

I will investigate these other locations!

If you want to actually talk with people about some of your thoughts on the industry, I'd recommend just going to a hotel bar, grab a pint, and just spark a conversation.

Apologies, I do kinda auto-repost my articles here without thinking whether they are paywalled (nearly everything I’ve written isn’t)

here is an unpaywalled link that anyone can access: https://www.owlposting.com/p/8157b515-56ce-40a4-a7f0-da6d46f...

edit: please subscribe if you enjoyed this! lots of really crazy articles + podcasts in this subfield are planned for the upcoming month :) all free!

Thanks, it was kind of frustrating especially as my first contact with a blog.

I don't disagree!

Thanks for posting this here! Sent this HN link to the founders, so they may be able to answer any Q's that people have

Happy to answer Qs. AMA

>molecules get screened against tox targets

sure! i cover this in the essay, the purpose of this dataset is not just toxicity, but repurposing also

>toxicity of major metabolites

this is planned (and also explicitly mentioned in the article)

>no need to worry about CYP’s

again, this is about more than just toxicity

>volume of distribution

i suppose, but this feels like a strange point to raise. this dataset doesnt account for a lot of things, no biological dataset does

>advertisement

to some degree: it is! but it is also one that is free for academic usage and the only one of its kind accessible to smaller biopharmas

My main point of skepticism about repurposing is whether this is giving any of new and actionable information. It seems to be reliant on pre existing target annotations, and qualified targets already have molecules designed for them. Is the off-target effect strong enough to give you a superior molecule? Why not just start by picking a qualified target and committing to designing a better molecule without doing all the off target assay stuff first?

I completely agree, but I also think there is some truth to the related statement: 'cancer research often isn't conducted in a way that is actually useful'!

For example, in-vivo tumor experiments in mice can yield completely different results depending on exactly where the tumor was implanted. E.g. a 'lung cancer mouse model' may have the lung cancer injected just under the skin, also known as subcutaneous tumor models, instead of in the lung! Entirely because it's a lot more efficient + yields more trustable data, but the results are often deeply disconnected from how the tumor would naturally grow + respond to drugs within its host organ.

thanks for posting this here!

Thanks for your posts! I've been very impressed with your ability to both be at the leading edge of knowledge and communicate the parts that are most interesting for a broad technical audience, it's an impressive skill.

<3 high praise, appreciate the kind words

Fixed!